These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 7834118)

  • 1. Potential to involve multiple effector cells with human recombinant interleukin-2 and antiganglioside monoclonal antibodies in a canine malignant melanoma immunotherapy model.
    Helfand SC; Soergel SA; Donner RL; Gan J; Hank JA; Lindstrom MJ; Sondel PM
    J Immunother Emphasis Tumor Immunol; 1994 Oct; 16(3):188-97. PubMed ID: 7834118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodies.
    Helfand SC; Hank JA; Gan J; Sondel PM
    Cell Immunol; 1996 Jan; 167(1):99-107. PubMed ID: 8548851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of cellular cytotoxicity and complement-mediated lysis of melanoma and neuroblastoma cells in vitro by murine antiganglioside antibodies MB 3.6 and 14.G2a.
    Mayer P; Handgretinger R; Bruchelt G; Schaber B; Rassner G; Fierlbeck G
    Melanoma Res; 1994 Apr; 4(2):101-6. PubMed ID: 8069095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The immunotherapeutic potential of activated canine alveolar macrophages and antitumor monoclonal antibodies in metastatic canine melanoma.
    Soergel SA; MacEwen EG; Vail DM; Potter DM; Sondel PM; Helfand SC
    J Immunother; 1999 Sep; 22(5):443-53. PubMed ID: 10546161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GD3 ganglioside antibody augments tumoricidal capacity of canine blood mononuclear cells by induction of interleukin 12.
    Helfand SC; Dickerson EB; Munson KL; Padilla ML
    Cancer Res; 1999 Jul; 59(13):3119-27. PubMed ID: 10397254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro.
    Hank JA; Surfus J; Gan J; Chew TL; Hong R; Tans K; Reisfeld R; Seeger RC; Reynolds CP; Bauer M
    J Immunother Emphasis Tumor Immunol; 1994 Jan; 15(1):29-37. PubMed ID: 8110728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibodies to disialogangliosides: characterization of antibody-mediated cytotoxicity against human melanoma and neuroblastoma cells in vitro.
    Kawashima I; Tada N; Fujimori T; Tai T
    J Biochem; 1990 Jul; 108(1):109-15. PubMed ID: 2121721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin.
    Honsik CJ; Jung G; Reisfeld RA
    Proc Natl Acad Sci U S A; 1986 Oct; 83(20):7893-7. PubMed ID: 3094017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro.
    Harel W; Shau H; Hadley CG; Morgan AC; Reisfeld RA; Cheresh DA; Mitchell MS
    Cancer Res; 1990 Oct; 50(19):6311-5. PubMed ID: 2400994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant antibodies against ganglioside expressed on tumor cells.
    Hanai N; Nakamura K; Shitara K
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S13-7. PubMed ID: 10950141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma.
    Albertini MR; Gan J; Jaeger P; Hank JA; Storer B; Schell K; Rivest T; Surfus J; Reisfeld RA; Schiller JH; Sondel PM
    J Immunother Emphasis Tumor Immunol; 1996 Jul; 19(4):278-95. PubMed ID: 8877722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent cellular cytotoxicity.
    Triozzi PL; Shah JJ; Wang WQ; Aldrich W; Edberg JC; Su K; Carlisle R; Conry R; LoBuglio AF; Forero A
    Cancer Biother Radiopharm; 2006 Dec; 21(6):553-60. PubMed ID: 17257070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2.
    Hank JA; Robinson RR; Surfus J; Mueller BM; Reisfeld RA; Cheung NK; Sondel PM
    Cancer Res; 1990 Sep; 50(17):5234-9. PubMed ID: 2386933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group.
    Frost JD; Hank JA; Reaman GH; Frierdich S; Seeger RC; Gan J; Anderson PM; Ettinger LJ; Cairo MS; Blazar BR; Krailo MD; Matthay KK; Reisfeld RA; Sondel PM
    Cancer; 1997 Jul; 80(2):317-33. PubMed ID: 9217046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells.
    Welt S; Carswell EA; Vogel CW; Oettgen HF; Old LJ
    Clin Immunol Immunopathol; 1987 Nov; 45(2):214-29. PubMed ID: 3665201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871.
    Liu Z; Lee FT; Hanai N; Smyth FE; Burgess AW; Old LJ; Scott AM
    Cancer Immun; 2002 Oct; 2():13. PubMed ID: 12747758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of lymphokine-activated killer (LAK) activity in canine lymphocytes with low dose human recombinant interleukin-2 in vitro.
    Helfand SC; Soergel SA; Modiano JF; Hank JA; Sondel PM
    Cancer Biother; 1994; 9(3):237-44. PubMed ID: 7820185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytolytic activity of murine anti-dog lymphoma monoclonal antibodies with canine effector cells and complement.
    Rosales C; Jeglum KA; Obrocka M; Steplewski Z
    Cell Immunol; 1988 Sep; 115(2):420-8. PubMed ID: 3409330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins.
    Cheresh DA; Pierschbacher MD; Herzig MA; Mujoo K
    J Cell Biol; 1986 Mar; 102(3):688-96. PubMed ID: 3005335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping effector functions of a monoclonal antibody to GD3 by characterization of a mouse-human chimeric antibody.
    Chapman PB; Gillies SD; Houghton AN; Reilly RM
    Cancer Immunol Immunother; 1994 Sep; 39(3):198-204. PubMed ID: 7522964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.